AC Immune (NASDAQ:ACIU – Get Free Report) will likely be announcing its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.74 million for the quarter.
AC Immune Trading Down 0.8 %
ACIU opened at $2.39 on Tuesday. The stock’s fifty day simple moving average is $2.65 and its 200 day simple moving average is $3.00. AC Immune has a 1-year low of $2.25 and a 1-year high of $4.98. The stock has a market cap of $236.47 million, a PE ratio of -5.20 and a beta of 1.23.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of AC Immune in a research note on Friday, November 15th.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than AC Immune
- How to Plot Fibonacci Price Inflection Levels
- How to Protect Your Portfolio When Inflation Is Rising
- Why Are Stock Sectors Important to Successful Investing?
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Insider Trading – What You Need to Know
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
